Pfizer Inc., the multinational pharmaceutical giant, has announced an agreement to acquire Metsera, a biotech firm focused on obesity and cardiovascular therapies, in a transaction valued at $4.9 billion.
Gatekeepers News reports that under the deal, disclosed in a Monday statement, Pfizer will purchase all outstanding Metsera shares for $47.50 each in cash.
The agreement also includes a contingent value right (CVR) of up to $22.50 per share tied to future regulatory and clinical milestones, potentially raising the total value beyond the initial figure.
The acquisition is set to add four clinical-stage programmes to Pfizer’s pipeline, featuring oral and injectable GLP-1 receptor agonists as well as amylin analogues.
Pfizer said these therapies have the potential to deliver best-in-class efficacy and safety profiles. Both companies’ boards have unanimously approved the deal.
Albert Bourla, Pfizer’s CEO, said the transaction strengthens the company’s position in the obesity drug market, which is rapidly expanding worldwide.
He said, “Obesity is linked to more than 200 health conditions. This acquisition aligns with our focus on the most impactful opportunities and propels Pfizer into this key therapeutic area.”
Whit Bernard, Metsera’s co-founder and CEO, described the partnership as a chance to accelerate the mission of reducing the physical, emotional, and economic toll of obesity.
Pfizer noted the acquisition is expected to close in the final quarter of 2025, subject to regulatory and shareholder approvals, and pledged to provide updated financial guidance in its next quarterly earnings release.
